A Multicenter, Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of 2 Oral Doses, 25 Mg Twice Daily and 100 Mg Twice Daily, of PG-760564 in Adult Patients With RA [rheumatoid arthritis] Receiving Methotrexate
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2011
At a glance
- Drugs PG 760564 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 07 Feb 2008 Status changed from recruiting to completed according to NCT.
- 19 Nov 2007 The expected completion date for this trial is now 1 Jan 2008.